Biotech Analyst Tewari discusses the launch opportunity for Argenx’s Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP) and next-gen immunotherapies in inflammation and immunology (I&I) disorders on an Analyst/Industry conference call to be held on May 17 at 2 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to EUR 470 from EUR 490 at JPMorgan
- Argenx price target lowered to $468 from $471 at JMP Securities
- Argenx Q1 2024: Strong Sales and Pipeline Progress
- Argenx reports Q1 EPS ($1.04), consensus (76c)
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update